post-bg-581
calendary January 27, 2023

The first registration certificate for a medicinal product was obtained under an accelerated procedure

In 2022, the so-called “accelerated” registration procedure for medicines for which there is a risk of inventory shortage was organized in Russia (read more about this phenomenon in previous articles). In December 2022, the first marketing authorization (MA) was obtained in the frame of this procedure.

The Ministry of Health of Russia approved the antitumor drug Pembroria (international non-proprietary name - Pembrolizumab). The application for registration was submitted at the beginning of July 2022. The holder of the RC is BIOCAD JSC. The entire production cycle of the drug is carried out in Russia.

Pembrolizumab is a humanized (very close to human in structure) monoclonal antibody, an inhibitor of PD-1 receptors, the blocking of which helps the body to recognize better tumor cells and fight them with its own immunity. Pembroria is indicated for the treatment of more than ten oncological diseases, including melanoma, cancer of the lung, kidney, endometrium, cervix, etc.

Pembroria is the first biosimilar to MSD's original Keytruda, which was first approved in the US in 2014 for the treatment of advanced or inoperable melanoma. In Russia, the original drug was registered in November 2016.

BIOCAD is currently conducting three phase I and III clinical trials of Pemboria, which should be completed in 2023, 2026 and 2027. As part of the study, the pharmacokinetics and safety of the Pembroria drug in comparison with the Keytruda drug, the effectiveness of the Pembroria drug in patients with unresectable or metastatic melanoma of the skin, as well as the immunogenicity of the drug in patients who previously received therapy in the clinical trials of the company BIOCAD is being estimated.

As already noted in the general article on the accelerated procedure, fast-track registration implies a number of limitations. In this case, the holder of the registration certificate (BIOCAD company), upon receipt of complete clinical trial data on efficacy and safety, will be required to submit a dossier for reassessment of the benefit/risk ratio.

The expiration date of the registration certificate is 02.12.2023.

References:
  1. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=6e0e88a9-b7b0-4969-b63c-b398541b3b39
  2. https://pharmvestnik.ru/content/news/Minzdrav-vydal-pervuu-registraciu-po-uskorennoi-procedure-v-ramkah-deficita.html

More related posts

new-img-1

Control

Fine for spa resort in Yessentuki

Roszdravnadzor has imposed a fine of 130 thousand rubles on a spa resort in Yessentuki for improper storage of medical products…

03.03.2016
READ ARTICLE
new-img-2

Roszdravnadzor

Roszdravnadzor – patients’ rights

In 2015, Roszdravnadzor restored the rights of more than 460 thousand citizens to effective, accessible, and safe medical…

03.03.2016
READ ARTICLE
new-img-3

Regulation

The certification scheme for medical products hasn’t changed recently

Roszdravnadzor informs that the certification scheme for products in the Russian Federation is determined by Decree of the…

03.04.2016
READ ARTICLE
new-img-4

Control

Fines – Rostov region

In one and a half months of 2016, the Local Agency of Roszdravnadzor in Rostov Region imposed fines of the total amount of…

03.10.2016
READ ARTICLE
new-img-5

Control

Unregistered medical products

Two citizens were fined for selling unregistered medicinal products on the Internet in the Republic of Bashkortostan.

03.10.2016
READ ARTICLE
new-img-6

Control

Unscheduled inspection by roszdravnadzor

Roszdravnadzor started an unscheduled inspection of the Federal State-Funded Institution of Sverdlovsk Region Kirovgrad Central…

03.14.2016
READ ARTICLE
new-img-7

Medical Devices

International medical device regulators forum (IMDRF)

The delegation of the Federal Service for Surveillance in Healthcare headed by Mikhail Murashko, Head of Roszdravnadzor,…

03.17.2016
READ ARTICLE
new-img-8

Pharmaceuticals

Roszdravnadzor has suspended a series of the preparation “Paratsetomol-UBF”

Roszdravnadzor has suspended a series of the preparation “Paratsetomol-UBF” in which pills the metal wire was found.

05.18.2016
READ ARTICLE
new-img-9

Roszdravnadzor

Medical equipment stands idle in the Pskov region

Roszdravnadzor (RZN) statement: the expensive medical equipment for the total amount of 342 million rubles stands idle in…

05.19.2016
READ ARTICLE
new-img-10

Control

Hospital control Jewish autonomous region

Roszdravnadzor has audited the activity of the Regional Budgetary Public Health Facility “Central district hospital of Lenin”…

05.20.2016
READ ARTICLE